{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-005246","form_type":"8-K","ticker":"TOI","cik":"0001799191","company_name":"Oncology Institute, Inc.","filed_at":"2022-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.264529+00:00","generated_at":"2026-06-27T01:14:16.281098+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TOI promotes Dr. Daniel Virnich to President and Dr. Matthew Miller to COO","bullets":["Dr. Daniel Virnich promoted from COO to President, effective March 15, 2022.","Dr. Matthew Miller promoted from Chief Administrative Officer to COO, effective same date.","Board approved RSU/option grants: CEO Hively $678K RSU + $1.38M options; Virnich $263K RSU + $533K options; Dalgleish $201K RSU + $407K options.","Updated 2021 compensation: Hively $11.6M, Virnich $7.6M, Dalgleish $4.8M total pay."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-005246","json":"https://secwatch.observer/filing/0001628280-22-005246.json","markdown":"https://secwatch.observer/filing/0001628280-22-005246.md","text":"https://secwatch.observer/filing/0001628280-22-005246.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799191/000162828022005246/0001628280-22-005246-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799191/000162828022005246/toi-20220302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T01:14:16.281098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c0005e185","claim":"Dr. Daniel Virnich changed role as President at Oncology Institute, Inc..","evidence_excerpt":"On March 2, 2022, the Board of Directors of The Oncology Institute, Inc. (the \"Company\") promoted Dr. Daniel Virnich to serve as President of the Company, effective as of March 15, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828022005246/0001628280-22-005246-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"45d2fe5a4b","claim":"Dr. Matthew Miller changed role as Chief Operating Officer at Oncology Institute, Inc..","evidence_excerpt":"On March 2, 2022, the Board of Directors of the Company promoted Dr. Matthew Miller to succeed Dr. Virnich as Chief Operating Officer, effective as of March 15, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828022005246/0001628280-22-005246-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}